425386-60-3 | Semagacestat

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$23.00	$17.00
5mg	98%	in stock	$69.00	$49.00
10mg	99%(HPLC)	in stock	$105.00	$74.00
25mg	99%(HPLC)	in stock	$208.00	$146.00
100mg	95%	in stock	$249.00	$174.00
250mg	95%	in stock	$463.00	$324.00

Description

• Catalog Number: AD28820
• Chemical Name: Semagacestat
• CAS Number: 425386-60-3
• Molecular Formula: C19H27N3O4
• Molecular Weight: 361.4354
• MDL Number: MFCD09970409
• SMILES: O=C([C@@H](NC(=O)[C@H](C(C)C)O)C)N[C@@H]1C(=O)N(C)CCc2c1cccc2

Computed Properties

• Complexity: 537
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 5
• XLogP3: 1.3

Literature

• A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

  The New England journal of medicine 20130725

• Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.

  Journal of medicinal chemistry 20130711

• The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.

  Drug metabolism and disposition: the biological fate of chemicals 20121001

• Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.

  Journal of clinical pharmacology 20120601

• The mechanism of γ-Secretase dysfunction in familial Alzheimer disease.

  The EMBO journal 20120516

• miR-9 controls the timing of neurogenesis through the direct inhibition of antagonistic factors.

  Developmental cell 20120515

• A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.

  Journal of neuropathology and experimental neurology 20120501

• First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.

  The Journal of biological chemistry 20120406

• Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.

  Journal of neurochemistry 20120401

• QT effect of semagacestat at therapeutic and supratherapeutic doses.

  International journal of clinical pharmacology and therapeutics 20120401

• Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120208

• A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.

  Journal of Alzheimer's disease : JAD 20120101

• Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.

  Neuro-degenerative diseases 20120101

• Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

  Current Alzheimer research 20120101

• Translatability scoring in drug development: eight case studies.

  Journal of translational medicine 20120101

• Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

  Expert opinion on drug discovery 20120101

• Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.

  PloS one 20120101

• Silencing of amyloid precursor protein expression using a new engineered delta ribozyme.

  International journal of Alzheimer's disease 20120101

• Alzheimer's disease and the amyloid cascade hypothesis: a critical review.

  International journal of Alzheimer's disease 20120101

• Centella asiatica Extract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action.

  International journal of Alzheimer's disease 20120101

• Alzheimer's disease: a clinical practice-oriented review.

  Frontiers in neurology 20120101

• Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes.

  PloS one 20120101

• Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20120101

• Inhibition of γ-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia.

  Molecular neurodegeneration 20120101

• Predicting cerebral amyloid angiopathy-related intracerebral hemorrhages and other cerebrovascular disorders in Alzheimer's disease.

  Frontiers in neurology 20120101

• γ-Secretase modulator in Alzheimer's disease: shifting the end.

  Journal of Alzheimer's disease : JAD 20120101

• pPKCα-mediated effect on in vitro Aβ production in response to gamma secretase inhibitor LY411575 in rat CTXTNA2 astrocytes.

  Journal of biological regulators and homeostatic agents 20120101

• Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.

  The Journal of pharmacology and experimental therapeutics 20111201

• [Gamma-secretase inhibitors and modulators].

  Nihon rinsho. Japanese journal of clinical medicine 20111201

• Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.

  Journal of medicinal chemistry 20111124

• Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

  Drugs 20111022

• Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.

  Expert opinion on investigational drugs 20110901

• Drugs: a tangled web of targets.

  Nature 20110713

• Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20110701

• ACS chemical neuroscience molecule spotlight on ELND006: another γ-secretase inhibitor fails in the clinic.

  ACS chemical neuroscience 20110615

• Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.

  Expert opinion on biological therapy 20110601

• Targets for AD treatment: conflicting messages from γ-secretase inhibitors.

  Journal of neurochemistry 20110501

• Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

  Expert opinion on investigational drugs 20110301

• Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.

  PLoS medicine 20110301

• What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

  Annals of neurology 20110201

• New pathway links γ-secretase to inflammation and memory while sparing notch.

  Annals of neurology 20110101

• Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.

  PloS one 20110101

• Selectivity to amyloid-β precursor protein cleavage provides hope against Alzheimer's.

  Alzheimer's research & therapy 20110101

• γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.

  Current topics in medicinal chemistry 20110101

• Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

  Journal of Alzheimer's disease : JAD 20110101

• Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

  International journal of Alzheimer's disease 20110101

• Therapeutic promise and challenges of targeting DLL4/NOTCH1.

  Vascular cell 20110101

• Globalization of Alzheimer's disease clinical trials.

  Alzheimer's research & therapy 20110101

• Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies.

  Alzheimer's research & therapy 20110101

• BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells.

  Journal of biomedical science 20110101

• Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

  Current medicinal chemistry 20110101

• Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease.

  Frontiers in endocrinology 20110101

• Genetics. Gamma-secretase and human disease.

  Science (New York, N.Y.) 20101119

• What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

  Biological psychiatry 20101115

• REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.

  CNS neuroscience & therapeutics 20101001

• Alzheimer's failure raises questions about disease-modifying strategies.

  Nature reviews. Drug discovery 20101001

• NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.

  Annals of neurology 20101001

• Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.

  Anticancer research 20101001

• ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).

  ACS chemical neuroscience 20100818

• [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100701

• Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20100401

• Piperidine-derived gamma-secretase modulators.

  Bioorganic & medicinal chemistry letters 20100201

• In response to 'a gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system'.

  Annals of neurology 20100101

• A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease.

  Alzheimer's research & therapy 20100101

• Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

  Journal of Alzheimer's disease : JAD 20100101

• Brain amyloid β protein and memory disruption in Alzheimer's disease.

  Neuropsychiatric disease and treatment 20100101

• Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.

  Alzheimer's research & therapy 20100101

• Could lysine supplementation prevent Alzheimer's dementia? A novel hypothesis.

  Neuropsychiatric disease and treatment 20100101

• Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?

  Journal of Alzheimer's disease : JAD 20100101

• Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.

  Alzheimer's research & therapy 20100101

• Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.

  Journal of medicinal chemistry 20091022

• Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.

  Journal of neurochemistry 20090901

• A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

  Annals of neurology 20090701

• Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

  Expert opinion on pharmacotherapy 20090701

• Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.

  Current opinion in investigational drugs (London, England : 2000) 20090701

• gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice.

  Biochemical and biophysical research communications 20090529

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090301

• Committed neuronal precursors confer astrocytic potential on residual neural precursor cells.

  Developmental cell 20090201

• Requirement of Notch activation during regeneration of the intestinal epithelia.

  American journal of physiology. Gastrointestinal and liver physiology 20090101

• Recent developments in Alzheimer's disease therapeutics.

  BMC medicine 20090101

• A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity.

  PloS one 20090101

• Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.

  Journal of medicinal chemistry 20081211

• Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.

  The Journal of pharmacology and experimental therapeutics 20081101

• Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells.

  Blood 20080901

• Molecule of the month. Semagacestat.

  Drug news & perspectives 20080901

• Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

  Archives of neurology 20080801

• A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers.

  Bioorganic & medicinal chemistry letters 20071115

• Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.

  Bioorganic & medicinal chemistry letters 20071101

• Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.

  The Journal of biological chemistry 20070824

• Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry.

  The Journal of pharmacology and experimental therapeutics 20070301

• Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.

  Clinical neuropharmacology 20070101

• Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

  The Journal of pharmacology and experimental therapeutics 20061201

• Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

  The Journal of pharmacology and experimental therapeutics 20061101

• [The molecular mechanism of Notch-induced transformation and the therapeutic potential of its inhibitor].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060701

• Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

  Neurology 20060227

• Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].

  The Journal of pharmacology and experimental therapeutics 20050501

• Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures.

  The Journal of pharmacology and experimental therapeutics 20050101

• Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

  Clinical neuropharmacology 20050101

• Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).

  The Journal of pharmacology and experimental therapeutics 20040401